Myelin Basic Protein (68-82), Guinea Pig Research Applicatio

Myelin Basic Protein (68-82), Guinea Pig: Research Applications, Mechanistic Insights, and Experimental Utility in Neuroimmunology
Introduction [Related: gm-6001]
Myelin Basic Protein (MBP) is a critical structural component of the myelin sheath in the central nervous system (CNS), playing a pivotal role in maintaining the integrity and function of myelinated axons. The MBP (68-82) peptide, derived from the guinea pig sequence, is a synthetic fragment corresponding to amino acids 68 through 82 of the full-length protein. This peptide has garnered significant attention in neuroimmunological research, particularly as a potent immunogen for the induction of experimental autoimmune encephalomyelitis (EAE)—a widely used animal model for multiple sclerosis (MS). The mechanism of action of MBP (68-82) centers on its ability to elicit T-cell mediated immune responses, leading to demyelination and neuroinflammation that closely recapitulate the pathophysiological features of MS in humans (Pettinelli & McFarlin, 1981, J Immunol). [Related: tcep]
The guinea pig MBP (68-82) sequence is highly immunogenic, making it a valuable tool for dissecting the cellular and molecular mechanisms underlying CNS autoimmunity. By serving as a defined antigenic epitope, this peptide enables precise experimental manipulation and reproducibility in EAE induction, facilitating the study of T-cell specificity, antigen processing, and the development of novel immunomodulatory therapies. [Related: z devd fmk]
Clinical Value and Applications
The primary clinical value of MBP (68-82), guinea pig, lies in its utility as a research reagent for modeling autoimmune demyelinating diseases. EAE induced by MBP (68-82) is considered the gold standard for preclinical evaluation of candidate therapeutics targeting MS and related disorders (Miller et al., 2010, Nat Rev Immunol). The model enables researchers to investigate the immunopathogenesis of CNS demyelination, including the roles of CD4+ T cells, cytokine networks, and blood-brain barrier disruption.
Key applications of MBP (68-82) include:
- **Induction of EAE in rodent models:** The peptide is used to reliably induce EAE in susceptible strains of rats and mice, providing a platform for studying disease onset, progression, and remission.
- **Evaluation of immunomodulatory agents:** MBP (68-82)-induced EAE serves as a preclinical model for testing the efficacy and safety of novel drugs, biologics, and cell-based therapies targeting autoimmune neuroinflammation.
- **Mechanistic studies:** The defined sequence allows for the analysis of antigen-specific T-cell responses, epitope spreading, and the molecular basis of immune tolerance and autoimmunity.
- **Biomarker discovery:** The model facilitates the identification of immunological and molecular biomarkers associated with disease activity and therapeutic response.
By enabling these applications, MBP (68-82), guinea pig, has become an indispensable tool in translational neuroscience and immunology research.
Key Challenges and Pain Points Addressed
Current treatments for MS and related demyelinating diseases are limited by incomplete efficacy, adverse effects, and an incomplete understanding of disease mechanisms. The MBP (68-82) peptide addresses several key challenges in this context:
- **Reproducibility and specificity:** Full-length MBP and crude myelin extracts can introduce variability due to heterogeneous antigenic content. The synthetic MBP (68-82) peptide offers a defined, reproducible antigen for experimental induction of autoimmunity (Kerlero de Rosbo et al., 1993, J Neuroimmunol).
- **Epitope mapping:** The use of a specific peptide fragment enables detailed mapping of T-cell epitopes and the study of antigenic determinants involved in disease initiation and progression.
- **Modeling relapsing-remitting and chronic disease:** MBP (68-82)-induced EAE can be tailored to produce different disease courses, closely mimicking the clinical heterogeneity observed in MS patients (Baxter, 2007, J Neuropathol Exp Neurol).
- **Therapeutic screening:** The model provides a robust platform for high-throughput screening of candidate therapeutics, accelerating the translation of basic research findings into clinical interventions.
By addressing these pain points, MBP (68-82), guinea pig, enhances the reliability and translational relevance of preclinical neuroimmunology research.
Literature Review
A substantial body of literature supports the use of MBP (68-82), guinea pig, in neuroimmunological research. Key studies include:
1. **Pettinelli & McFarlin (1981, J Immunol):** This seminal study demonstrated that synthetic MBP (68-82) peptide could induce EAE in Lewis rats, establishing the foundation for peptide-induced models of CNS autoimmunity. The authors showed that the peptide elicited robust T-cell responses and demyelinating pathology comparable to that induced by whole MBP.
2. **Kerlero de Rosbo et al. (1993, J Neuroimmunol):** The authors investigated the immunodominant epitopes of MBP in EAE, identifying MBP (68-82) as a critical determinant of disease susceptibility and severity. This work underscored the importance of epitope specificity in autoimmune pathogenesis.
3. **Baxter (2007, J Neuropathol Exp Neurol):** This review highlighted the utility of MBP (68-82)-induced EAE in modeling different clinical phenotypes of MS, including relapsing-remitting and chronic-progressive forms. The study emphasized the translational value of the model for therapeutic development.
4. **Miller et al. (2010, Nat Rev Immunol):** The authors provided a comprehensive overview of EAE models, noting the advantages of peptide-induced EAE for dissecting antigen-specific immune responses and evaluating targeted immunotherapies.
5. **Sospedra & Martin (2005, Annu Rev Immunol):** This review discussed the role of MBP epitopes, including MBP (68-82), in the pathogenesis of MS and the development of antigen-specific tolerance strategies.
6. **Kawakami et al. (2004, Nat Med):** The study used MBP (68-82)-specific T-cell receptor transgenic mice to elucidate the mechanisms of T-cell-mediated CNS inflammation, providing insights into the cellular basis of autoimmune demyelination.
7. **Bettelli et al. (2003, J Exp Med):** The authors explored the role of regulatory T cells in MBP (68-82)-induced EAE, highlighting the potential for immunomodulatory interventions targeting specific T-cell subsets.
Collectively, these studies establish MBP (68-82), guinea pig, as a cornerstone reagent for experimental neuroimmunology.
Experimental Data and Results
Experimental induction of EAE using MBP (68-82), guinea pig, typically involves immunization of susceptible rodent strains (e.g., Lewis rats, C57BL/6 mice) with the peptide emulsified in complete Freund’s adjuvant (CFA), often accompanied by pertussis toxin to enhance disease penetrance (Pettinelli & McFarlin, 1981, J Immunol). The resulting clinical syndrome is characterized by ascending paralysis, weight loss, and histopathological evidence of CNS inflammation and demyelination.
Key experimental findings include:
- **Disease induction:** MBP (68-82) reliably induces EAE with a predictable onset and severity, facilitating controlled studies of disease mechanisms and therapeutic interventions (Kerlero de Rosbo et al., 1993, J Neuroimmunol).
- **Immunopathology:** Histological analysis reveals perivascular infiltration of mononuclear cells, demyelination, and axonal damage, closely mirroring MS pathology (Baxter, 2007, J Neuropathol Exp Neurol).
- **T-cell responses:** The peptide elicits robust proliferation of CD4+ T cells, predominantly of the Th1 and Th17 phenotypes, which are implicated in CNS tissue damage (Kawakami et al., 2004, Nat Med).
- **Therapeutic modulation:** Administration of immunomodulatory agents (e.g., interferon-beta, monoclonal antibodies) in MBP (68-82)-induced EAE models has demonstrated efficacy in reducing disease severity and promoting recovery, validating the model’s translational relevance (Miller et al., 2010, Nat Rev Immunol).
These experimental results underscore the value of MBP (68-82), guinea pig, as a reproducible and mechanistically informative tool for preclinical research.
Usage Guidelines and Best Practices
To maximize the utility and reproducibility of MBP (68-82), guinea pig, in experimental settings, the following guidelines are recommended:
- **Peptide preparation:** Dissolve the lyophilized peptide in sterile water or PBS at the recommended concentration (typically 1–2 mg/mL). Ensure complete solubilization and filter sterilize if necessary.
- **Immunization protocol:** Emulsify the peptide with an equal volume of CFA containing Mycobacterium tuberculosis H37Ra (4 mg/m Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 50 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541566